Sritharan Sharanya K, Arifin Amar Harris, Salvamani Shamala, Koh Rhun Yian, Gunasekaran Baskaran
Division of Applied Biomedical Sciences and Biotechnology, School of Health Sciences, IMU University, Kuala Lumpur, Malaysia.
Centre for Postgraduate Studies, IMU University, Kuala Lumpur, Malaysia.
Funct Integr Genomics. 2025 Jun 2;25(1):115. doi: 10.1007/s10142-025-01610-4.
Long stress-induced non-coding transcript 5 (LSINCT5) is a long non-coding RNA (lncRNA) that has been demonstrated to exhibit oncogenic properties as its upregulation was found to be commonly associated with malignant clinicopathological features in various cancers. Numerous studies have reported that LSINCT5 overexpression may promote cancer progression by regulating the expression of genes that modulate important aspects of cell activity and by interfering with signalling pathways via precise mechanisms such as microRNA (miRNA) sponging, protein interactions, as well as acting as a downstream target of transcription factors. Eventually, these processes stimulate malignant behaviour such as proliferation, invasion, migration, and epithelial-mesenchymal transition (EMT). Research suggests LSINCT5 could be a useful biomarker and therapeutic target. However, understanding their complex nature and impact on physiological processes is crucial for determining their oncogenic properties and potential use in therapy. This review focuses on LSINCT5's biological functions, expression patterns, oncogenic roles, and molecular mechanisms in cancers. We further highlight the potential of LSINCT5 as a biomarker for early diagnosis and prognosis, as well as a therapeutic target in cancer therapy.
长应激诱导非编码转录本5(LSINCT5)是一种长链非编码RNA(lncRNA),已被证明具有致癌特性,因为其上调通常与多种癌症的恶性临床病理特征相关。大量研究报告称,LSINCT5的过表达可能通过调节影响细胞活动重要方面的基因表达,以及通过诸如微小RNA(miRNA)海绵作用、蛋白质相互作用等精确机制干扰信号通路,还通过作为转录因子的下游靶点来促进癌症进展。最终,这些过程会刺激增殖、侵袭、迁移和上皮-间质转化(EMT)等恶性行为。研究表明,LSINCT5可能是一种有用的生物标志物和治疗靶点。然而,了解它们的复杂性质及其对生理过程的影响对于确定其致癌特性和在治疗中的潜在用途至关重要。本综述重点关注LSINCT5在癌症中的生物学功能、表达模式、致癌作用和分子机制。我们进一步强调了LSINCT5作为早期诊断和预后生物标志物以及癌症治疗中治疗靶点的潜力。
Funct Integr Genomics. 2025-6-2
Curr Med Chem. 2023
Eur Rev Med Pharmacol Sci. 2019-6
Medicine (Baltimore). 2014-12
Hum Cell. 2021-9
Biochem Biophys Res Commun. 2018-5-30
Nat Rev Genet. 2024-8
Front Oncol. 2024-2-1
Yale J Biol Med. 2023-12
Yale J Biol Med. 2023-12
Chin Med J (Engl). 2023-7-5